Epidemiology and Risk Factors for (Tardive) Dyskinesia

Abdolmaleky, 2005, Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope, Am. J. Pharmacogenomics, 5, 149, 10.2165/00129785-200505030-00002 Ascher-Svanum, 2008, Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study, J. Clin. Psychiatry, 69, 1580, 10.4088/JCP.v69n1008 Bakker, 2008, Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions, Mol. Psychiatry, 13, 544, 10.1038/sj.mp.4002142 Barnes, 2003, The Barnes Akathisia Rating Scale—revisited, J. Psychopharmacol., 17, 365, 10.1177/0269881103174013 Barnes, 1983, Tardive dyskinesia: a 3-year follow-up study, Psychol. Med., 13, 71, 10.1017/S003329170005008X Bergen, 1988, AIMS ratings—repeatability, Br. J. Psychiatry, 152, 670, 10.1192/bjp.152.5.670 Bergen, 1989, The course of tardive dyskinesia in patients on long-term neuroleptics, Br. J. Psychiatry, 154, 523, 10.1192/bjp.154.4.523 Bergen, 1984, Tardive dyskinesia: fluctuating patient or fluctuating rater, Br. J. Psychiatry, 144, 498, 10.1192/bjp.144.5.498 Boks, 2000, The specificity of neurological signs in schizophrenia: a review, Schizophr. Res., 43, 109, 10.1016/S0920-9964(99)00145-0 Burke, 1982, Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs, Neurology, 32, 1335, 10.1212/WNL.32.12.1335 Burke, 1988, Tardive dystonia: clinical aspects and treatment, Adv. Neurol., 49, 199 Cacabelos, 2010, Genomics and Pharmacogenomics of Schizophrenia, CNS Neurosci. Ther. Cannon, 2002, Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort, Arch. Gen. Psychiatry, 59, 449, 10.1001/archpsyc.59.5.449 Caroff, 2011, Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia, J. Clin. Psychiatry, 72, 295, 10.4088/JCP.09m05793yel Casey, 2004, Pathophysiology of antipsychotic drug-induced movement disorders, J. Clin. Psychiatry, 65, 25 Chakos, 1996, Incidence and correlates of tardive dyskinesia in first episode of schizophrenia, Arch. Gen. Psychiatry, 53, 313, 10.1001/archpsyc.1996.01830040049009 Chatterjee, 1995, Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients, Am. J. Psychiatry, 152, 1724, 10.1176/ajp.152.12.1724 Chouinard, 1988, A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases, J. Clin. Psychopharmacol., 8, 21S Chouinard, 2005, Manual for the Extrapyramidal Symptom Rating Scale (ESRS), Schizophr. Res., 76, 247, 10.1016/j.schres.2005.02.013 Correll, 2007, One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review, J. Child Adolesc. Psychopharmacol., 17, 647, 10.1089/cap.2006.0117 Correll, 2004, Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies, Am. J. Psychiatry, 161, 414, 10.1176/appi.ajp.161.3.414 Correll, 2009, Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials, Schizophr. Bull., 35, 443, 10.1093/schbul/sbn018 Correll, 2008, Tardive dyskinesia and new antipsychotics, Curr. Opin. Psychiatry, 21, 151, 10.1097/YCO.0b013e3282f53132 Cortese, 2005, Relationship of neuromotor disturbances to psychosis symptoms in first-episode neuroleptic-naive schizophrenia patients, Schizophr. Res., 75, 65, 10.1016/j.schres.2004.08.003 Dean, 2004, Clinical rating scales and instruments: how do they compare in assessing abnormal, involuntary movements?, J. Clin. Psychopharmacol., 24, 298, 10.1097/01.jcp.0000125681.97466.e7 Dragt, 2011, Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk, Schizophr. Res., 125, 69, 10.1016/j.schres.2010.09.007 2000 Ellingrod, 2002, Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6, Pharmacotherapy, 22, 1416, 10.1592/phco.22.16.1416.33700 Emsley, 2004, A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia, J. Clin. Psychiatry, 65, 696, 10.4088/JCP.v65n0516 Emsley, 2005, Neurological abnormalities in first-episode schizophrenia: temporal stability and clinical and outcome correlates, Schizophr. Res., 75, 35, 10.1016/j.schres.2004.06.014 Erlenmeyer-Kimling, 2000, Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project, Am. J. Psychiatry, 157, 1416, 10.1176/appi.ajp.157.9.1416 Faurbye, 1964, Neurological Symptoms in Pharmacotherapy of Psychoses, Acta Psychiatr. Scand., 40, 10, 10.1111/j.1600-0447.1964.tb05731.x Fenton, 2000, Prevalence of spontaneous dyskinesia in schizophrenia, J. Clin. Psychiatry, 61, 10 Fernandez, 2001, The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up, Neurology, 56, 805, 10.1212/WNL.56.6.805 Gottesman, 2003, The endophenotype concept in psychiatry: etymology and strategic intentions, Am. J. Psychiatry, 160, 636, 10.1176/appi.ajp.160.4.636 Guy, 1976 Guy, W. A. (1976). CDEU Assessment Manual for Psychopharmacology —Revised. (DHEW Publ No ADM 76-338). U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville. Hirvonen, 2005, Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia, Arch. Gen. Psychiatry, 62, 371, 10.1001/archpsyc.62.4.371 Hori, 2000, Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia, Neuropsychopharmacology, 23, 170, 10.1016/S0893-133X(99)00156-6 Howes, 2009, The dopamine hypothesis of schizophrenia: version III–the final common pathway, Schizophrenia bulletin, 35, 549, 10.1093/schbul/sbp006 Jeste, 1995, Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients, Arch. Gen. Psychiatry, 52, 756, 10.1001/archpsyc.1995.03950210050010 Jeste, 2000, Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone, Am. J. Psychiatry, 157, 1150, 10.1176/appi.ajp.157.7.1150 Jones, 1994, Child development risk factors for adult schizophrenia in the British 1946 birth cohort, Lancet, 344, 1398, 10.1016/S0140-6736(94)90569-X Kane, 2009, Akathisia: an updated review focusing on second-generation antipsychotics, J. Clin. Psychiatry, 70, 627, 10.4088/JCP.08r04210 Kane, 1984, Incidence of tardive dyskinesia: five-year data from a prospective study, Psychopharmacol. Bull., 20, 387 Kapur, 2001, Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis, Am. J. Psychiatry, 158, 360, 10.1176/appi.ajp.158.3.360 Koning, 2011 Koning, 2008, Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis, Schizophr. Bull., 36, 723, 10.1093/schbul/sbn146 Koning, 2010, Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis, Schizophr. Bull., 36, 723, 10.1093/schbul/sbn146 Koning, 2011, Movement disorders in nonpsychotic siblings of patients with non-affective psychosis, Psychiatr. Res., 188, 133, 10.1016/j.psychres.2011.01.005 Kraepelin, 1919 Margolese, 2005, Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction, Can. J. Psychiatry, 50, 541, 10.1177/070674370505000907 McCreadie, 1994, Movement disorder in never and minimally treated Nigerian schizophrenic patients, Br. J. Psychiatry, 164, 184, 10.1192/bjp.164.2.184 McCreadie, 1996, Abnormal movements in never-medicated Indian patients with schizophrenia, Br. J. Psychiatry, 168, 221, 10.1192/bjp.168.2.221 McCreadie, 2003, Spontaneous dyskinesia in first-degree relatives of chronically ill, never-treated people with schizophrenia, Br. J. Psychiatry, 183, 45, 10.1192/bjp.183.1.45 Miller, 2007, Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis, J. Clin. Psychiatry, 68, 1901, 10.4088/JCP.v68n1210 Mittal, 2008, Longitudinal progression of movement abnormalities in relation to psychotic symptoms in adolescents at high risk of schizophrenia, Arch. Gen. Psychiatry, 65, 165, 10.1001/archgenpsychiatry.2007.23 Morgenstern, 1993, Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study, Arch. Gen. Psychiatry, 50, 723, 10.1001/archpsyc.1993.01820210057007 Murray, 1998, Predictors of outcome in schizophrenia, J. Clin. Psychopharmacol., 18, 2S, 10.1097/00004714-199804001-00002 Oosthuizen, 2003, Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol, J. Clin. Psychiatry, 64, 1075, 10.4088/JCP.v64n0913 Owens, 1982, Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics, Arch. Gen. Psychiatry, 39, 452, 10.1001/archpsyc.1982.04290040052008 Pappa, 2009, Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review, Psychol. Med., 39, 1065, 10.1017/S0033291708004716 Patsopoulos, 2005, CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis, Pharmacogenet. Genomics, 15, 151, 10.1097/01213011-200503000-00003 Peralta, 2010, Motor behavior abnormalities in drug-naive patients with schizophrenia spectrum disorders, Mov. Disord., 25, 1068, 10.1002/mds.23050 Schooler, 2005, Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial, Am. J. Psychiatry, 162, 947, 10.1176/appi.ajp.162.5.947 Silvestri, 2000, Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study, Psychopharmacology (Berl), 152, 174, 10.1007/s002130000532 Strous, 2004, Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects, Schizophr. Bull., 30, 265, 10.1093/oxfordjournals.schbul.a007077 Tenback, 2005, Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study, J. Clin. Psychiatry, 66, 1130, 10.4088/JCP.v66n0907 Tenback, 2006, Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study, Am. J. Psychiatry, 163, 1438, 10.1176/appi.ajp.163.8.1438 Tenback, 2006, Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances, Neuropsychopharmacology, 31, 1832, 10.1038/sj.npp.1301044 Tenback, 2007, Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study, Compr. Psychiatry, 48, 436, 10.1016/j.comppsych.2007.05.003 Tenback, 2009, Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis, Mov. Disord., 24, 2309, 10.1002/mds.22707 Tenback, 2010, Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia, J. Psychopharmacol., 24, 1031, 10.1177/0269881109106306 Tenback, D. E., and van Harten, P. N. (2011). Movement disorders Schizofrenia Manual (W. Cahn. Utrecht, De Tijdstroom) Thelma, 2008, Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics, Pharmacogenomics, 9, 1285, 10.2217/14622416.9.9.1285 Tiwari, 2005, Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms, Schizophr. Res., 75, 21, 10.1016/j.schres.2004.12.011 Tiwari, 2005, Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism, Pharmacogenomics J., 5, 60, 10.1038/sj.tpj.6500282 van Harten, 1997, The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curacao Extrapyramidal Syndromes Study II, Schizophr. Res., 26, 235, 10.1016/S0920-9964(97)00058-3 van Harten, 2006, Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curacao extrapyramidal syndromes study V, J. Clin. Psychiatry, 67, 1920, 10.4088/JCP.v67n1212 van Harten, 2009, Movement disorders should be a criterion for schizophrenia in DSM-V, Psychol. Med., 39, 1754, 10.1017/S0033291709990456 van Os, 1997, Tardive dyskinesia: who is at risk?, Acta Psychiatr. Scand., 96, 206, 10.1111/j.1600-0447.1997.tb10153.x van Rossum, 2009, Bipolar disorder and dopamine dysfunction: an indirect approach focusing on tardive movement syndromes in a naturalistic setting, BMC Psychiatry, 9, 16, 10.1186/1471-244X-9-16 van Os, 2009, Schizophrenia, Lancet, 374, 635, 10.1016/S0140-6736(09)60995-8 Zai, 2010, Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes, Prog. Neuropsychopharmacol. Biol. Psychiatry, 34, 50, 10.1016/j.pnpbp.2009.09.020 Zai, 2010, The catechol-O-methyl-transferase gene in tardive dyskinesia, World J. Biol. Psychiatry, 11, 803, 10.3109/15622975.2010.486043 Zhang, 2010, D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis, Am. J. Psychiatry, 167, 763, 10.1176/appi.ajp.2009.09040598 Zhou, 2009, Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I, Clin. Pharmacokinet., 48, 689, 10.2165/11318030-000000000-00000 Zhou, 2009, Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II, Clin. Pharmacokinet., 48, 761, 10.2165/11318070-000000000-00000